CN104491612A - Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy - Google Patents

Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy Download PDF

Info

Publication number
CN104491612A
CN104491612A CN201410760396.XA CN201410760396A CN104491612A CN 104491612 A CN104491612 A CN 104491612A CN 201410760396 A CN201410760396 A CN 201410760396A CN 104491612 A CN104491612 A CN 104491612A
Authority
CN
China
Prior art keywords
parts
chinese medicine
medicine composition
rhizoma
diabetic retinopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410760396.XA
Other languages
Chinese (zh)
Inventor
邓凤桂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Original Assignee
GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd filed Critical GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Priority to CN201410760396.XA priority Critical patent/CN104491612A/en
Publication of CN104491612A publication Critical patent/CN104491612A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Abstract

The invention belongs to the field of traditional Chinese medicines, in particular relates to a purpose of a traditional Chinese medicine composition in preparing a medicament for treating diabetic retinopathy and aims at solving the deficiencies in the prior art that the traditional chemical treatment medicament for the diabetic retinopathy is large in hepatotoxicity and poor in curative effect. The traditional Chinese medicine composition for treating or preventing the diabetic retinopathy is mainly prepared from the following medicinal raw materials in parts by weight: 17 parts of astragaloside, 16 parts of desertliving cistanche, 10 parts of rhizoma smilacis glabrae, 12 parts of Chinese arborvitae twig, 8 parts of rhizoma alismatis, 9 parts of rhizoma coptidis, 10 parts of prepared rehmannia root, 8 parts of gentian, 18 parts of bighead atractylodes rhizome, 16 parts of dandelion, 8 parts of pinellia ternate, 8 parts of gardenia, 10 parts of virgate wormwood herb and 18 parts of licorice. The traditional Chinese medicine composition is good in curative effect of treating or preventing the diabetic retinopathy, is low in side effect of the medicament and has remarkable clinical popularization value.

Description

Chinese medicine composition becomes the purposes in medicine in preparation treatment of diabetic retinopathy
Technical field
The invention belongs to field of medicaments, be specifically related to the purposes of a kind of Chinese medicine composition in preparation treatment of diabetic retinopathy change medicine.
Background technology
Diabetic renal papillary necrosis is the consequence of diabetic microangiopathy, and because diabetes cause retinal capillary wall to damage, blood is hypercoagulability in addition, easily causes thrombosis and blood stasis, even angiorrhexis.At present, the retinopathy that diabetes cause causes VI and blind main cause.This disease morbidity early stage patient is without any sensation, if make regular check on optical fundus, doctor can see whether your optical fundus changes, and is at this moment the best opportunity of prevention.Mid-term there will be retinal edema, and eye may occur new vessels and hemorrhage to vitreous chamber.Now can feel blurred vision, have shadow to wave at the moment, metamorphopsia etc.During late period, vitreous hemorrhage is serious, retina shedding, even blind.
Mainly there are laser therapy and Drug therapy two kinds of modes in the retinopathy caused for diabetes clinically at present. and wherein retinal laser therapy is the basic means that treatment of diabetic retinopathy becomes, directly can solidify closed new vessels, microangioma and have the blood capillary of fluorescence leakage, laser therapy makes part retinal tissue by laser photocoagulation, remaining retina can obtain abundanter blood oxygen supply, blocking-up new vessels produces, thus stops the development of retinopathy.But this treatment means only can play retarding action for diabetic retinopathy, the treatment situation for conditions of patients is poor, and medical expense is high, and patient is difficult to bear.The incidence rate that Drug therapy effectively can reduce diabetic ocular fundus diseases is carried out for diabetics, and Drug therapy also can play direct therapeutical effect to diabetic retinopathy usually.Western medicine effectively cannot treat diabetic ophthalmopathy, and long-term taking Western medicine has more side effect, Chinese medicine curative effect in treatment is better, the symptom such as vitreous hemorrhage, macular edema caused for diabetes when having had at present the treatment of multiple Chinese medicine preparation such as peace snow granule, sugared net soup, discharge opeing soup for diabetic retinopathy has must mitigation, but still it is not satisfied to there is therapeutic effect, the defect that relapse rate is high.Therefore, still there is very large demand for effective medicine of diabetic ophthalmopathy in medical care patient.The present invention, namely from pathogeny and the clinical symptoms of diabetic ophthalmopathy, provides that a kind of particularly diabetic retinopathy can treating both the principal and secondary aspects of a disease to diabetic retinopathy, the medicine that relapse rate is low.
Summary of the invention
For the deficiency of current diabetic renal papillary necrosis clinical treatment medicine, the object of the present invention is to provide the purposes of a kind of Chinese medicine composition in preparation treatment of diabetic retinopathy change medicine, this Chinese medicine composition has the treatment advantage that therapeutic effect is remarkable, side effect is little, permanence operation is good when treatment of diabetic retinopathy becomes, have fine medical application prospect.Chinese medicine composition of the present invention, according to components by weight percent meter, it obtains primarily of the raw material of following weight portion: the Radix Astragali 17 parts, Herba Cistanches 16 parts, Rhizoma Smilacis Glabrae 10 parts, Cacumen Platycladi 12 parts, Rhizoma Alismatis 8 parts, Rhizoma Coptidis 9 parts, 10 parts, Radix Rehmanniae Preparata, Radix Gentianae 8 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Herba Taraxaci 16 parts, the Rhizoma Pinelliae 8 parts, Fructus Gardeniae 8 parts, Herba Artemisiae Scopariae 10 parts, 18 parts, Radix Glycyrrhizae.
In Chinese medicine composition described above, various Chinese medicinal components is all got its conventional agents area and is used as medicine.The mutual compatible combination of said medicine in the present invention, complements one another, and reaches the object of blood sugar lowering, antiinflammatory, liver heat removing and eyesight improving, has good curative effect to diabetic renal papillary necrosis.
Fructus Lycii 8 parts, Herba Ecliptae 14 parts, the Radix Paeoniae Alba 10 parts can also be contained in the present invention's Chinese medicine composition described above.Fructus Lycii, Herba Ecliptae, the Radix Paeoniae Alba three kinds of medicines are used in conjunction, and not only significantly can improve the microangiopathies situation of patient, and three kinds of medicines and aforementioned pharmaceutical compositions coupling of the present invention can strengthen its therapeutic effect to diabetic renal papillary necrosis further.
The method preparing Chinese medicine composition of the present invention is as follows: each medical material getting above-mentioned components by weight percent, adds the 5-15 water doubly of medical material gross weight, soaks 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 60-90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.The above-mentioned Chinese medicine composition of the present invention can be prepared into pharmaceutical preparation conventional clinically further, is preferably mixture, tablet, capsule.
By pharmacodynamic experiment, the present invention confirms that Chinese medicine composition causes rat diabetes retinopathy for streptozotocin and has good therapeutic effect.Compare with model group, Chinese medicine composition high and low dose group and positive group all can reduce EB value (P<0.05), obvious reduction E/P(P<0.01), and can retinal morphology be recovered, Chinese medicine composition high and low dose group also obviously can reduce retinal tissue MDA value, raise its SOD value (P<0.01), and positive group little on the impact of SOD and MDA.
In a word, the present invention compared with prior art, have the activity that fine treatment of diabetic retinopathy becomes, and the present invention is pure Chinese medicinal preparation, to human body particularly to liver avirulence.When the present invention uses as diabetic renal papillary necrosis medicine, drug effect is comprehensive, while blood sugar lowering antiinflammatory, liver heat removing and eyesight improving, effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness can also be obtained, the mutual compatible combination of ladies and gentlemen's medicine, complements one another, and plays synergism, the object strengthening immunologic function can be reached, and Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, be suitable for popular use, there is good application prospect.
Detailed description of the invention
Further describe the present invention below by way of detailed description of the invention, but the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they are all deemed to be included within scope of the present invention.
the preparation of Part I, Chinese medicine composition of the present invention
embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: the Radix Astragali 17 parts, Herba Cistanches 16 parts, Rhizoma Smilacis Glabrae 10 parts, Cacumen Platycladi 12 parts, Rhizoma Alismatis 8 parts, Rhizoma Coptidis 9 parts, 10 parts, Radix Rehmanniae Preparata, Radix Gentianae 8 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Herba Taraxaci 16 parts, the Rhizoma Pinelliae 8 parts, Fructus Gardeniae 8 parts, Herba Artemisiae Scopariae 10 parts, 18 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75%(v/v), leave standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 2 Chinese medicine composition mixture of the present invention
Prescription: the Radix Astragali 17 parts, Herba Cistanches 16 parts, Rhizoma Smilacis Glabrae 10 parts, Cacumen Platycladi 12 parts, Rhizoma Alismatis 8 parts, Rhizoma Coptidis 9 parts, 10 parts, Radix Rehmanniae Preparata, Radix Gentianae 8 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Herba Taraxaci 16 parts, the Rhizoma Pinelliae 8 parts, Fructus Gardeniae 8 parts, Herba Artemisiae Scopariae 10 parts, 18 parts, Radix Glycyrrhizae, Fructus Lycii 8 parts, Herba Ecliptae 14 portions of Radix Paeoniae Albas 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75%(v/v), leave standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 3 Chinese medicine composition tablet of the present invention
Prescription: the Radix Astragali 17 parts, Herba Cistanches 16 parts, Rhizoma Smilacis Glabrae 10 parts, Cacumen Platycladi 12 parts, Rhizoma Alismatis 8 parts, Rhizoma Coptidis 9 parts, 10 parts, Radix Rehmanniae Preparata, Radix Gentianae 8 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Herba Taraxaci 16 parts, the Rhizoma Pinelliae 8 parts, Fructus Gardeniae 8 parts, Herba Artemisiae Scopariae 10 parts, 18 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 4 Chinese medicine composition tablet of the present invention
Prescription: the Radix Astragali 17 parts, Herba Cistanches 16 parts, Rhizoma Smilacis Glabrae 10 parts, Cacumen Platycladi 12 parts, Rhizoma Alismatis 8 parts, Rhizoma Coptidis 9 parts, 10 parts, Radix Rehmanniae Preparata, Radix Gentianae 8 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Herba Taraxaci 16 parts, the Rhizoma Pinelliae 8 parts, Fructus Gardeniae 8 parts, Herba Artemisiae Scopariae 10 parts, 18 parts, Radix Glycyrrhizae, Fructus Lycii 8 parts, Herba Ecliptae 14 parts, the Radix Paeoniae Alba 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 5 Chinese medicinal composition capsules agent of the present invention
Prescription: the Radix Astragali 17 parts, Herba Cistanches 16 parts, Rhizoma Smilacis Glabrae 10 parts, Cacumen Platycladi 12 parts, Rhizoma Alismatis 8 parts, Rhizoma Coptidis 9 parts, 10 parts, Radix Rehmanniae Preparata, Radix Gentianae 8 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Herba Taraxaci 16 parts, the Rhizoma Pinelliae 8 parts, Fructus Gardeniae 8 parts, Herba Artemisiae Scopariae 10 parts, 18 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
embodiment 6 Chinese medicinal composition capsules agent of the present invention
Prescription: the Radix Astragali 17 parts, Herba Cistanches 16 parts, Rhizoma Smilacis Glabrae 10 parts, Cacumen Platycladi 12 parts, Rhizoma Alismatis 8 parts, Rhizoma Coptidis 9 parts, 10 parts, Radix Rehmanniae Preparata, Radix Gentianae 8 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Herba Taraxaci 16 parts, the Rhizoma Pinelliae 8 parts, Fructus Gardeniae 8 parts, Herba Artemisiae Scopariae 10 parts, 18 parts, Radix Glycyrrhizae, Fructus Lycii 8 parts, Herba Ecliptae 14 parts, the Radix Paeoniae Alba 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
the pharmacodynamics of Part II, Chinese medicine composition of the present invention is investigated
embodiment 7 Chinese medicine composition composition oral preparation causes the effect of rat diabetes retinopathy to streptozotocin
1 animal grouping and modeling
SD rat 150, after adaptability raises one week, wherein normally feeds for 10 as a control group, after all the other Rat Fast 12h, prepares diabetes model by 50mg/kg left lower quadrant intracavitary administration 2% streptozotocin (STZ) solution.Streptozotocin solution is in configuring with 0.1mmol/L, pH4.5 citrate buffer solution before use.Matched group injects isodose citric acid, sodium citrate buffer solution.Detect the non-fasting glucose of rat tail vein after injection 72h, blood glucose value >=16.7mmol/L is defined as diabetes rat.Grouping and administration: modeling starts to calculate the course of disease after one week and starts administration.Get into mould rat 100 and be only divided into 5 groups at random by body weight, blood sugar level: Chinese medicine composition object height, in and low dose group, model group (normal saline), positive group.Each group all by dosage gastric infusion in table 1, every day 1 time, successive administration 4 weeks.Survey rat body weight weekly, to determine dosage.
2 testing indexs and assay method
2.1 Evans blue tracer quantitative assay retinal blood vessels leak amounts
Often group gets 6 rats, after anesthesia, EB liquid is slowly injected through tail vein by 45mg/kg dosage, can be observed large rathole and whole skin and become blue instantaneously, circulate after 120 minutes, open thoracic cavity and expose heart, mosquito forceps clamping postcava, by the capable left ventricle perfusion of ventricles liquid being preheated to 37 DEG C, cut off right auricle simultaneously, perfusion pressure 120mmHg (about 164cmH20), perfusion continues 3 minutes, to remove endovascular EB.After perfusion terminates, take out eyeball immediately, careful separation goes out retina, spends the night to dry and weighs.Retina and 150 μ L Methanamides are hatched 18 hours at 70 DEG C, then extract are moved in centrifuge tube, centrifuge at 4 DEG C, centrifugal 90min under 6000rpm/min.Get supernatant 100 μ L microplate reader and survey its absorbance (A) value, measure the absorption photometric value under 620nm and 740nm two kinds of wavelength respectively, get two value differences and the clean absorption photometric value final absorbance as sample.Each sample measures 3 times, and 5 seconds, interval, finally gets its meansigma methods, then tries to achieve EB concentration in sample according to EB standard solution absorbance difference in Methanamide.With retina dry weight (mg) standardization EB (ng) content, result is expressed as: ng/mg.
2.2 Biochemical Indexes and retinal morphology are observed
2.2.1 sample collection
After last administration, each group Rat Fast water 12h, measures blood glucose value, then etherization, vacuum test tube Culling heart blood, separation of serum; Extract rat eye, left eye is placed in 10% formalin solution and is fixed for retinal microvasculopathy reason and morphological observation, and right eye is blunt separation retina under condition of ice bath immediately, for detecting SOD activity, MDA content.
2.2.2 retinal tissue section and observation
Immunohistochemistry is observed: the formaldehyde eyeball taken off being placed in 10% is fixed on fixes 48h, removing anterior ocular segment is that eyecup is cut into three pieces by Fructus Citri tangerinae lobe sample, isolate retina, running water 24h, put into 3% trypsin solution of the Tris-HCl buffer solution with 0.1ml/L, pH7.8,37 DEG C of water bath with thermostatic control 80min, when after retinal tissue protein dissolution, retina is moved in water, vibrate gently, until the retinal blood pipe network of remaining layer of transparent, move on microscope slide, natural drying, PAS adds brazilwood extract dyeing.The retinal capillary morphological change of observation by light microscope rat, adopt computerized image analysis sgstem quantitative analysis, to the blood capillary of every routine retina digestion specimen, count the endotheliocyte in 5 visuals field and pericyte, calculate the ratio (E/P) of endotheliocyte and pericyte.
3 statistical analysis
Experimental data represents with mean ± S.D., adopts SPSS software, and statistical test uses t inspection and single factor test F in groups to check, test level α=0.05.
4, result of the test and analysis
Chinese medicine composition composition oral preparation on the impact of rat diabetes retinopathy, macular edema in table 1, table 2.To make in retinal tissue after rat modeling success that SOD vigor reduces, MDA content and E/P raise and there is the rising of EB value, there is the phenomenons such as edema is hemorrhage in retina, model group has significant difference compared with normal group.Compare with model group, Chinese medicine composition high and low dose group and positive group all can reduce EB value (P<0.05), obvious reduction E/P(P<0.01), and can retinal morphology be recovered, Chinese medicine composition high and low dose group also obviously can reduce retinal tissue MDA value, raise its SOD value (P<0.01), and positive group little on the impact of SOD and MDA.
Table 1 Chinese medicine composition composition oral preparation is on the impact of rat diabetes retinopathy
Group Dosage EB value
Normal group Gavage equal-volume normal saline 12.28±0.52
Model group Gavage equal-volume normal saline 38.36±1.28
Positive controls Gavage gives the Calcium Dobesilate of 150mg/kg/d 24.17±0.96 *
Breviscapine group Gavage gives the breviscapine of 7mg/kg/d 34.27±1.15
Low group of Chinese medicine composition Gavage gives the Chinese medicine composition of 7mg/kg/d 21.38±0.88 *#▲
Chinese medicine composition object height group Gavage gives the Chinese medicine composition of 70mg/kg/d 19.85±0.74 **#▲
Compare with model group, *p < 0.05, *p < 0.01; Compared with positive controls, #p < 0.05; ##p < 0.01
Compared with breviscapine group, ▲p < 0.05, ▲ ▲p < 0.01;
Table 2 Chinese medicine composition composition oral preparation is on the impact of diabetic renal papillary necrosis rat SOD, MDA and E/P
Group SOD(U.mg -1) MDA(nmol.mg -1) E/P
Normal group 9.85±0.88 3.97±0.64 2.62±0.34
Model group 4.97±0.78 6.05±0.72 5.73±0.55
Positive controls 6.22±0.92 * 5.48±0.57 * 4.62±0.52 *
Breviscapine group 5.07±0.61 5.88±0.68 5.45±0.44 *
Low group of Chinese medicine composition 6.36±0.78 *▲▲ 5.33±0.62 *▲ 4.36±0.46 *▲
Chinese medicine composition object height group 6.79±0.66 *#▲▲ 5.05±0.46 *#▲▲ 4.19±0.36 *#▲
Compare with model group, *p < 0.05, *p < 0.01; Compared with positive controls, #p < 0.05; ##p < 0.01
Compared with breviscapine group, ▲p < 0.05, ▲ ▲p < 0.01.

Claims (4)

1. the purposes of a Chinese medicine composition in preparation treatment of diabetic retinopathy change medicine, it is characterized in that, described Chinese medicine composition obtains primarily of the raw material of following weight portion: the Radix Astragali 17 parts, Herba Cistanches 16 parts, Rhizoma Smilacis Glabrae 10 parts, Cacumen Platycladi 12 parts, Rhizoma Alismatis 8 parts, Rhizoma Coptidis 9 parts, 10 parts, Radix Rehmanniae Preparata, Radix Gentianae 8 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Herba Taraxaci 16 parts, the Rhizoma Pinelliae 8 parts, Fructus Gardeniae 8 parts, Herba Artemisiae Scopariae 10 parts, 18 parts, Radix Glycyrrhizae.
2. purposes as claimed in claim 1, it is characterized in that, described Chinese medicine composition contains Fructus Lycii 8 parts, Herba Ecliptae 14 parts and the Radix Paeoniae Alba 10 parts.
3. purposes as claimed in claim 1 or 2, it is characterized in that, described Chinese medicine composition is mixture, tablet or capsule.
4. purposes as claimed in claim 3, it is characterized in that, the preparation method of described Chinese medicine composition comprises the following steps: get each medical material, add the 5-15 water doubly of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 60-90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.
CN201410760396.XA 2014-12-12 2014-12-12 Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy Pending CN104491612A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410760396.XA CN104491612A (en) 2014-12-12 2014-12-12 Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410760396.XA CN104491612A (en) 2014-12-12 2014-12-12 Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy

Publications (1)

Publication Number Publication Date
CN104491612A true CN104491612A (en) 2015-04-08

Family

ID=52933126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410760396.XA Pending CN104491612A (en) 2014-12-12 2014-12-12 Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy

Country Status (1)

Country Link
CN (1) CN104491612A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105267632A (en) * 2015-10-13 2016-01-27 青岛辰达生物科技有限公司 Traditional Chinese medicine composition composition treating diabetic macular edema
CN107583003A (en) * 2016-07-08 2018-01-16 香港大学 Prevention or compound, the preparation method and use for the treatment of diabetic eye diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192914A (en) * 1997-03-11 1998-09-16 孙松 Fuming capsule and preparing method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192914A (en) * 1997-03-11 1998-09-16 孙松 Fuming capsule and preparing method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
刘静: "中药治疗糖尿病性视网膜病变的临床观察", 《中医杂志》 *
王纯庠等: "中医药治疗糖尿病视网膜病变回眸研究", 《中西医结合心脑血管病杂志》 *
蔡国华等: "中西医结合治疗糖尿病视网膜病变30例临床观察", 《新中医》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105267632A (en) * 2015-10-13 2016-01-27 青岛辰达生物科技有限公司 Traditional Chinese medicine composition composition treating diabetic macular edema
CN107583003A (en) * 2016-07-08 2018-01-16 香港大学 Prevention or compound, the preparation method and use for the treatment of diabetic eye diseases

Similar Documents

Publication Publication Date Title
CN103099959B (en) Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof
CN102205107B (en) Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof
CN103301412A (en) Traditional Chinese medicine composition for treating alcoholic liver
CN103845418B (en) A kind of Chinese medicine composition for the treatment of retinal hemorrhage and uses thereof
CN103041208A (en) Chinese herbal preparation for treating climacteric syndrome of women, and preparation method thereof
CN102772712B (en) Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot
CN104083640B (en) Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof
CN105412410A (en) Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy
CN104435487A (en) Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof
CN102846824B (en) Traditional Chinese medicinal composition for treating cold dampness blood stasis blocking channel type diabetic feet, and its preparation method
CN104491612A (en) Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy
CN106237131A (en) The Herba Taraxaci oral liquor of lowering blood-fat and reducing weight and oral liquid thereof
CN104689079A (en) Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method thereof
CN105343593A (en) Spica prunellae health oral liquid capable of decreasing blood pressure and blood lipid as well as preparation method of spica prunellae health oral liquid
CN104922448A (en) Traditional Chinese medicine composition for treating fundus hemorrhage and application thereof
CN104644967A (en) Pharmaceutical composition for treating I-type diabetes and application thereof
CN104547798A (en) Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof
CN104474255A (en) Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition
CN105267632A (en) Traditional Chinese medicine composition composition treating diabetic macular edema
CN102988747B (en) Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof
CN109528865A (en) It is a kind of for treating the Chinese materia medica preparation and preparation method thereof of person in middle and old age&#39;s ophthalmology disease
CN103989940A (en) Traditional Chinese medicine composition for treating diabetes mellitus
CN106728835B (en) A kind of Chinese medicine for treating diabetes
CN113304235A (en) Traditional Chinese medicine composition and preparation method and application thereof
CN104324139B (en) A kind of pharmaceutical composition treating xerophthalmia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150408